‹ All stocks
Enveric Biosciences
ENVB · NASDAQ · Healthcare
$1.47
▲ $1.47 (0.38%)
Day range
$1.42 – $1.47
Year range
$1.17 – $13.25
Open
$1.46
Previous close
—
Market cap
$6.56M
Volume (24h)
$7.5K
Volume (52w)
$11.05K
Performance
7D
▼ -0.31%
1M
▲ 3.20%
3M
▲ 1.07%
6M
▼ -25.23%
1Y
▼ -82.39%
YTD
▼ -60.07%
3Y
▼ -99.64%
5Y
▼ -99.99%
All-time
▼ -100.00%
Key statistics
P/E ratio
-0.12
EPS (TTM)
$-11.80
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
4.5M
About Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Visit websiteCountry: United States of America
More in Healthcare
LLY Eli Lilly and Company |
$1143.12 | -0.59% |
JNJ Johnson & Johnson |
$252.93 | -2.22% |
ABBV AbbVie |
$265.76 | 2.20% |
MRK Merck & Co. |
$139.54 | -2.97% |
UNH UnitedHealth Group Incorp… |
$378.58 | 3.66% |